Fidelity Investments
MBRX icon

Fidelity Investments’s Moleculin Biotech MBRX Stock Holding History

Fidelity Investments’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7 Buy
+3
New +$10 ﹤0.01% 5383
2025
Q2 		– Sell
-1
Closed -$33 – 5431
2025
Q1 		$33 Buy
+1
New +$34 ﹤0.01% 5187
2023
Q4 		– Hold
0
– -$1 – 5565
2023
Q3 		– Hold
0
– – – 5259
2023
Q2 		– Hold
0
– – – 5351
2023
Q1 		– Hold
0
– – – 5235
2022
Q4 		– Hold
0
– – – 5318
2022
Q3 		– Hold
0
– – – 5204
2022
Q2 		– Hold
0
– – – 5264

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM

Fidelity Investments's MBRX Position: Q1 2026 in Review

Fidelity Investments opened a new position in Moleculin Biotech (MBRX) in Q1 2026: 3 shares worth $7. The stake represents ﹤0.01% of the portfolio and ranks #5383 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in MBRX as recently as Q1 2025.

Fidelity Investments first reported a position in MBRX in Q1 2025 and has held it in 2 quarters since. The position peaked at $33 in Q1 2025. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Fidelity Investments held 3 shares of Moleculin Biotech worth $7 as of Q1 2026.
  • Moleculin Biotech was a new Fidelity Investments position in Q1 2026.
  • Moleculin Biotech made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5383 holding.
  • Fidelity Investments first reported a position in Moleculin Biotech in Q1 2025 and has held it in 2 quarters since.
  • Fidelity Investments's Moleculin Biotech position peaked at $33 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.